Loading...
Avacta Group Plc
AVCTF•PNK
Healthcare
Biotechnology
$0.71
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $11.89M in Q2 2023 to $11.26M in Q2 2024. Gross profit remained healthy with margins at 27% in Q2 2024 compared to 42% in Q2 2023. Operating income hit -$15.34M last quarter, sustaining a consistent -136% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$4.51M. Net income rose to -$12.47M, while earnings per share reached -$0.04. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan